These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38785762)

  • 21. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.
    Albuquerque AM; Eckert I; Tramujas L; Butler-Laporte G; McDonald EG; Brophy JM; Lee TC
    Clin Microbiol Infect; 2023 Jan; 29(1):13-21. PubMed ID: 35863630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated with baricitinib: a comparative study from the national centre of Hungary.
    Gáspár Z; Szabó BG; Andrikovics H; Ceglédi A; Rajmon M; Ábrahám A; Várnai Z; Kiss-Dala N; Szlávik J; Sinkó J; Vályi-Nagy I; Lakatos B
    Geroscience; 2024 Jun; 46(3):2863-2877. PubMed ID: 38367195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of Tocilizumab in COVID-19 Patients and Benefit of Single-Dose: The Largest Retrospective Observational Study.
    Al-Qaaneh AM; Al-Ghamdi FH; AbdulAzeez S; Borgio JF
    Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35335998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison.
    Hamed DM; Belhoul KM; Al Maazmi NA; Ghayoor F; Moin M; Al Suwaidi M; Narainen M; Makki M; AbdulRahman M
    J Infect Public Health; 2021 Aug; 14(8):985-989. PubMed ID: 34153729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.
    Cardona-Pascual I; Berlana D; Martinez-Valle F; Campany-Herrero D; Montoro-Ronsano JB
    Med Clin (Barc); 2022 Apr; 158(7):301-307. PubMed ID: 34147248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.
    Trøseid M; Arribas JR; Assoumou L; Holten AR; Poissy J; Terzić V; Mazzaferri F; Baño JR; Eustace J; Hites M; Joannidis M; Paiva JA; Reuter J; Püntmann I; Patrick-Brown TDJH; Westerheim E; Nezvalova-Henriksen K; Beniguel L; Dahl TB; Bouscambert M; Halanova M; Péterfi Z; Tsiodras S; Rezek M; Briel M; Ünal S; Schlegel M; Ader F; Lacombe K; Amdal CD; Rodrigues S; Tonby K; Gaudet A; Heggelund L; Mootien J; Johannessen A; Møller JH; Pollan BD; Tveita AA; Kildal AB; Richard JC; Dalgard O; Simensen VC; Baldé A; de Gastines L; Del Álamo M; Aydin B; Lund-Johansen F; Trabaud MA; Diallo A; Halvorsen B; Røttingen JA; Tacconelli E; Yazdanpanah Y; Olsen IC; Costagliola D;
    Crit Care; 2023 Jan; 27(1):9. PubMed ID: 36627655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
    RECOVERY Collaborative Group
    Lancet; 2022 Jul; 400(10349):359-368. PubMed ID: 35908569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019.
    Tziolos N; Karofylakis E; Grigoropoulos I; Kazakou P; Koullias E; Savva A; Kranidioti H; Pelekanou A; Boulouta A; Pirounaki M; Tsiodras S; Georgiopoulos G; Boumpas DT; Kavatha D; Thomas K; Vassilopoulos D; Antoniadou A
    Open Forum Infect Dis; 2022 Jan; 9(1):ofab588. PubMed ID: 34988257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics.
    Elhazmi A; Rabie AA; Al-Omari A; Mufti HN; Sallam H; Alshahrani MS; Mady A; Alghamdi A; Altalaq A; Azzam MH; Sindi A; Kharaba A; Al-Aseri ZA; Almekhlafi GA; Tashkandi W; Alajmi SA; Faqihi F; Alharthy A; Al-Tawfiq JA; Melibari RG; Arabi YM
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study.
    Aljuhani O; Korayem GB; Altebainawi AF; Al Harthi A; Badreldin HA; Alsalloum MA; Eljaaly K; Alharbi A; Aljehani R; Vishwakarma R; Alenazi AA; Alalawi M; Alissa A; Al Aamer K; Al Enazi H; Almusallam M; Alshehri A; Bukhari R; Alasmari G; AlQahtani MM; Al Shammari S; Alsulaymi HO; Al Sulaiman K
    J Intensive Care Med; 2023 Jun; 38(6):534-543. PubMed ID: 36683420
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.
    Cardona-Pascual I; Berlana D; Martinez-Valle F; Campany-Herrero D; Montoro-Ronsano JB
    Med Clin (Engl Ed); 2022 Apr; 158(7):301-307. PubMed ID: 35531306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tocilizumab in the Management of COVID-19: A Preliminary Report.
    Li M; Yoo EJ; Baram M; McArthur M; Skeehan C; Awsare B; George G; Summer R; Zurlo J; Jallo J; Roman J
    Am J Med Sci; 2021 Feb; 361(2):208-215. PubMed ID: 33358502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective Observational Study of Complete Blood Count (CBC) Parameters and ICU Mortality of COVID-19 Disease in Delta Variant and Omicron Variant in a Community-Based Hospital in New York City.
    Yadav R; Yadav V; Pokhriyal S; Zahid U; Gandhi A
    Cureus; 2023 Feb; 15(2):e34894. PubMed ID: 36925973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study.
    Masotti L; Landini G; Panigada G; Grifoni E; Tarquini R; Cei F; Cimolato BMA; Vannucchi V; Di Pietro M; Piani F; Fortini A; Faraone A; Nenci G; Cipollini F; Blanc P; Lotti P; Di Natale M; Risaliti F; Aquilini D; Seravalle C; Bribani A; Farsi A; Micheletti I; Cioni E; Pelagalli G; Mattaliano C; Pinto G; Madonia EM; Sivieri I; Mannini M; Valoriani A; Brancati S; Rosselli M; Pavone E; Burla MC; Sergi A;
    Int Immunopharmacol; 2022 Jun; 107():108709. PubMed ID: 35334359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tocilizumab and Baricitinib for Recovery From Acute Exacerbation of Combined Pulmonary Fibrosis and Emphysema Secondary to COVID-19 Infection: A Case Report.
    Kai Y; Matsuda M; Suzuki K; Kasamatsu T; Kajita A; Uno K; Muro S
    Cureus; 2022 Mar; 14(3):e23411. PubMed ID: 35481309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
    Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC;
    Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
    Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K
    Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between tocilizumab treatment of hyperinflammatory patients with COVID-19 in a critical care setting and elevated incidence of hospital-acquired bacterial and invasive fungal infections.
    Minihan B; McAuliffe E; Powell J; Wong SL; Wilkie K; Murphy C; Maher A; Power L; O'Connell NH; Dunne CP
    J Hosp Infect; 2022 Aug; 126():29-36. PubMed ID: 35472487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early use of tocilizumab in patients with severe pneumonia secondary to severe acute respiratory syndrome coronavirus 2 infection and poor prognostic criteria: Impact on mortality rate and intensive care unit admission.
    Sánchez-Rovira P; Pérez-Chica G; Ortega-Granados AL; Aguilar-García J; Díaz-Beltrán L; Gálvez-Montosa F; García-Verdejo F; Luque-Caro N; Quero-Blanco C; Fernández-Navarro M; Rodríguez-Sánchez A; Ruiz-Bailén M; Yaguez-Mateos L; Marín-Pozo JF; Sierra-Torres MI; Lacárcel-Bautista C; Duro-Ruiz GJ; Duro-Fernández MÁ; García-Alegría J; Herrero-Rodríguez C
    Medicine (Baltimore); 2021 Jul; 100(29):e26533. PubMed ID: 34398008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis.
    Steuber TD; Rosandich T; Cadwallader T; Steil L; Belk M; Yendrapalli U; Hassoun A; Edwards J
    Ann Pharmacother; 2024 Apr; 58(4):391-397. PubMed ID: 37522616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.